Medical Benefit Drug Policy
UnitedHealthcare medical benefit drug policy governing intravitreal administration of specified VEGF and dual VEGF/Ang-2 inhibitors (Avastin, Beovu, Byooviz, Cimerli, Eylea and related products) including general requirements, continuation requirements, diagnosis-specific proven/medically necessary indications, compounding guidance for bevacizumab, and a long list of applicable HCPCS and ICD-10 codes for ophthalmologic diagnoses.
Updated list of applicable ICD-10 diagnosis codes to reflect annual edits; added H40.841, H40.842, H40.843, and H40.849.
Archived previous policy version 2025D0042AN.
Applicable Codes updated.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.